- About Us
- Who We Serve
- Our Tissues & Products
- Contact Us
Coverage of human placental membrane allografts for chronic wounds by second largest commercial health plan in the nation enhances access to wound healing innovation
EDISON, N.J. (March 14, 2019) — MTF Biologics® announced today that its AmnioBand® Membrane line of aseptically processed human placental membrane allografts for use as acute or chronic wound coverings have received coverage from Anthem Insurance Companies, Inc.
“We are pleased that Anthem is now covering our AmnioBand allograft solutions,” said Kim Rounds, Vice President of Wound Care at MTF Biologics. “As a nonprofit and the nation’s leading tissue bank, we are extremely pleased by Anthem’s decision to include AmnioBand for the treatment of diabetic foot ulcers. Our expanding portfolio, including viable cryopreserved placental membranes, ambient storage placental tissues, and AlloPatch® Pliable (a human derived reticular dermal matrix), provides wound care professionals and their patients with some of the most safe, clinically proven and cost effective treatment options for chronic wounds.”
As the second largest commercial health insurer in the nation, Anthem provides coverage to roughly one in eight Americans with more than 40 million members across the nation. Under the policy statement, AmnioBand is considered medically necessary when used for the treatment of diabetic foot ulcers that have not healed with standard conservative therapy.
“More than 30 million Americans have diabetes, and 25 percent of these individuals will experience a diabetic foot ulcer in their lifetime,” said Rounds. “Chronic wounds remain a significant health challenge facing millions of Americans each year. AmnioBand has proven clinical results to act as an aid in the treatment of chronic non-healing wounds, and Anthem’s decision to cover the innovation reflects the impact of our research and dedication to saving and healing lives.”
Coverage for AmnioBand within Anthem is effective immediately.
For more information about MTF Biologics and AmnioBand®, please visit www.mtfbiologics.org.
About MTF Biologics
MTF Biologics®, also known as the Musculoskeletal Transplant Foundation, is a nonprofit organization based in Edison, N.J. It is a consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions, and governed by a board of surgeons who are leading experts in tissue transplantation. As the world’s largest tissue bank, MTF Biologics saves and heals lives by honoring donated gifts, serving patients and advancing science. Since its inception in 1987, the organization has received tissue from more than 132,000 donors and distributed more than 8.6 million grafts for transplantation. Through its IIAM subsidiary, it has placed more than 58,000 non-transplantable organs for research. Through its Statline subsidiary, it has managed more than 11.3 million donor referrals. For more information, visit www.mtfbiologics.org.
Media Contact for MTF Biologics: Christian Lail, 615-610-0307, Christian.email@example.com